This page is updated frequently with new Monoclonal-related patent applications.
|Foxc1 antibodies and methods of their use|
In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human foxc1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer.
John Wayne Cancer Institute
|Cell culture process for producing a protein|
The invention provides the mammalian cell culture process for the production of monoclonal antibodies and fusion proteins wherein the mammalian cell is cultured in suitable cell culture conditions specifically maintaining monophasic temperature.. .
|Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)|
Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (tfpi) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-tfpi monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided..
Bayer Healthcare Llc
|Neutralizing antibodies and methods of use thereof|
This invention provides monoclonal antibodies that recognize the toll-like receptor 4/md-2 receptor complex, and monoclonal antibodies that recognize the tlr4/md2 complex as well as tlr4 when not complexed with md-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics.
|Antibodies to tau and uses thereof|
monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including alzheimer's disease, progressive supranuclear palsy and pick's disease.. .
Eli Lilly And Company
|Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3|
The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with a monoclonal antibody against immune checkpoint molecule tim-3.. .
Bavarian Nordic A/s
|Antibodies specific for 4,6-diamino-5-(formylamino)pyrimidine and uses thereof|
The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (fapy-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to fapy-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.. .
Florida State University Research Foundation, Inc.
|Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature|
The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment of the present invention, and (b) a therapeutically effective amount of a combination therapy including bevacizumab and at least one additional therapeutic agent; or a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of a cox-2 inhibitor (coxib), a non-steroidal anti-inflammatory drug (nsaid), a prostaglandin e2 (pge2) synthase inhibitor, and combinations thereof.
The United States Of America, As Represented By The Secretary, Department Of Health And Human
|Transgenic animals capable of producing humanized ige at much higher levels than mouse ige|
The transgenic non-human animals are constructed, in whose genome the coding sequences of one of the animal's endogenous immunoglobulin cγ constant regions are replaced by human immunoglobulin cε constant region coding sequences. The transgenic animal is mouse, in whose genome the cγ1 constant regions are replaced by the human immunoglobulin cε constant regions and the cκ constant region is replaced by the human immunoglobulin cκ constant region.
Allermabs Co. Ltd.
|Therapeutic agent for inflammatory disease|
The present invention relates to a therapeutic agent for inflammation in which histone is involved, the agent comprising a monoclonal antibody or an antigen binding fragment thereof which binds to a peptide consisting of an amino acid sequence represented by ssvlyggppsaa (seq id no:1) or a conjugate of the peptide and a pharmaceutically acceptable carrier.. .
Josai University Corporation
Anti-gp73 monoclonal antibodies and methods of obtaining the same
Disclosed herein are antibodies and methods of using said antibodies to detect golgi protein 73 (gp73) and fucosylated gp73 in a sample.. .
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a molecularly targeted agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (vh), which includes an amino acid sequence selected from seq id no:1, seq id no:3, seq id no:5, and seq id no:7; and (ii) a light chain variable region (vl), which includes an amino acid sequence selected from seq id no:2, seq id no:4, seq id no:6, and seq id no:8.
The United States Of America, As Represented By The Secretary, Department Of
The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity agent..
Glaxosmithkline Intellectual Property Management Limited
Feeding strategies and purification processes for monoclonal antibody production
This invention provides an improved process for manufacturing a rabies monoclonal antibody (humab 17c7) that results in low osmolality, minimum secondary metabolites like ammonia and lactate, enhanced cell growth and productivity, minimum aggregation or degradation of monoclonal antibody during purification, thereby improving potency of monoclonal antibody (humab 17c7) as compared to human rabies immunoglobulin (hrig).. .
Serum Institute Of India Private Limited
Hybridoma cell lines (my-c-cc0c2-235-3h8) and use thereof for producing a monoclonal antibody against the human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)
monoclonal antibodies, which can be produced in vitro, against cardiac epitopes of the human my-c are produced by generating myeloma cell clones that produce such specific antibodies having epitope specificity. These monoclonal antibodies allow, among other things, the creation of an enzyme-linked immunosorbent assay (elisa) for the specific, cross-reactivity-free quantitative determination of my-c in serum, plasma, whole blood or other body fluid.
Cd-20-specific antibodies and methods of employing same
The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to cd20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting b cells or in treating b cell disorders.
Disclosed are an anti-human tim-3 antibody having high adcc activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of tim-3 or its three-dimensional structure and exhibits adcc activity; a hybridoma which produces the antibody; a dna encoding the antibody; a vector comprising the dna; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.. .
Kyushu University, National University Corporation
Monoclonal antibodies to programmed death 1 (pd-1)
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.
Preventing, treating, and reducing (persistent) post-traumatic headache
Disclosed herein are methods of treating or reducing incidence of post-traumatic headache and/or at least one secondary symptom associated with post-traumatic headache in a subject comprising administering to the subject a monoclonal antibody that modulates the cgrp pathway. Compositions for use in the disclosed methods are also provided.
Teva Pharmaceuticals International Gmbh
Methods for diagnosing and treating helicobacter pylori infection
The present invention provides methods for diagnosing and treating helicobacter pylori infection by using a monoclonal antibody to detect helicobacter pylori neutrophil-activating protein (hp-nap) and inhibit the activity thereof. The monoclonal antibody is an anti-flag antibody that binds to a specific epitope on hp-nap for the detection of hp-nap in its native form or denatured form.
National Tsing Hua University
Novel polypeptide binding to extracellular domain of epidermal growth factor receptor
The present invention relates to a polypeptide capable of binding specifically to the extracellular domain of epidermal growth factor receptor, a polynucleotide that encodes the polypeptide, an expression vector comprising the polynucleotide, a recombinant microorganism having the expression vector introduced therein, and a method of producing the polypeptide using the recombinant microorganism. The polypeptide according to the present invention can bind to the extracellular domain of epidermal growth factor receptor with a high binding affinity comparable to those of existing monoclonal antibodies that are widely used as targeted therapeutic agents, thereby inhibiting the activity of the epidermal growth factor receptor.
Korea Advanced Institute Of Science And Technology
Human monoclonal antibody human cd134 (ox40) and methods of making and using same
The invention provides antibodies that specifically bind to ox40 (cd134), referred to as ox40 antibodies, anti-ox40 or anti-ox40 antibodies. Invention antibodies that specifically bind to ox40 include mammalian (human, primate, etc.), humanized and chimeric anti-ox40 antibodies.
Kyowa Hakko Kirin Co., Ltd.
Antagonist anti-cd40 monoclonal antibodies and methods for their use
Compositions and methods of therapy for treating diseases mediated by stimulation of cd40 signaling on cd40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-cd40 antibody or antigen-binding fragment thereof to a patient in need thereof.
Novartis Vaccines And Diagnostics, Inc.
Anti-il-17 antibodies, producing same and using same
The present invention relates to the field of medicine, and specifically to the field of monoclonal antibodies against human il-17. More specifically, the invention relates to monoclonal antibodies/antagonists of il-17a, which bind with high affinity to an il-17 epitope, wherein the antibodies contain amino acid substitutions in hypervariable regions of heavy and light chains.
Closed Joint Stock Company "biocad"
High-throughput single cell sorting using microbubble well arrays
The present invention provides a microfabricated device and methods for high throughput single cell screening of a heterogeneous population. The present invention is partly based upon but not limited to sorting by monitoring cell secreted factors that accumulate in time (hours, days, weeks) as cells are cultured in the microbubble well niche the architecture of which facilitate the accumulation.
Nidus Biosciences, Llc
Humanized monoclonal antibodies and methodsof use
The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene vh1-69. This antibody is derived from mab g6 and recognizes the same epitope.
Dana-farber Cancer Institute, Inc.
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (fra) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to fra-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors.
Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function
Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
St. Jude Children's Research Hospital
Methods of evaluating quality of a chromatography media which binds anti-a or anti-b antibodies
Embodiments described herein relate to methods of evaluating quality of a chromatography media for removal of anti-a or anti-b antibodies from a sample, where the methods employ use of purified monoclonal igm-a and igm-b antibodies.. .
Merck Patent Gmbh
Enhancing serological assays via fusion proteins
A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (acyf) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention..
Methods and materials for the detection of dengue virus infection
The present invention provides monoclonal antibodies that are specific for the dengue non-structural glycoprotein ns1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including elisa and lateral flow assays, that employ the disclosed antibodies for the early detection of dengue virus infection. Diagnostic kits for the detection of dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies..
Inbios International, Inc.
High affinity and aggregatively stable antibodies on the basis of variable domains vl and a derivative vhh
The monoclonal igg-type antibodies were suggested comprising variable domains represented by a combination of vhh-derivative with a variable domain of the light chain vl. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (kabat numbering) or combinations thereof.
Closed Joint Stock Company "biocad"
Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular
Monoclonal antibodies against her2 epitope and methods of use thereof
This invention provides fully human monoclonal antibodies that recognize her2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications..
Mersana Therapeutics, Inc.
Production of hersintuzumab: a new humanized antibody against her2 for cancer treatment
A monoclonal anti-her2 antibody is mutated on complementarity determining regions (cdrs) and framework regions. The vh domain of the antibody includes a portion of the amino acid sequence as seq id no: 1.
Monoclonal antibody against human prpc and use thereof
A monoclonal antibody against human prpc protein capable of reducing the expression level of transcription factor twist1 in a targeting mode and inducing macrophage and nk cells to target to rectal cancer tumor cells. The combined drug therapy with the antibody and cetuximab also exhibits inhibitory effect on tumor better than administration of the antibody or cetuximab alone..
Institute Of Zoology, Chinese Academy Of Sciences
Monoclonal antibodies that neutralize a norovirus
monoclonal neutralizing antibodies are disclosed that specifically bind to a norovirus. In some embodiments, the norovirus is a genogroup ii norovirus or a genogroup ii norovirus.
The United States Of America, As Represented By The Secretary, Department Of Health And Human